FindTrial
Sign In

A study comparing Levetiracetam and Valproic Acid in preventing seizure in children diagnosed with neurocystcercosis.

Levetiracetam vs Valproic acid as monotherapy for prevention of recurrent seizures in childhood Neurocysticercosis - A Randomised open labelled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/01/017368
Enrollment
50
Registered
2019-01-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G060- Intracranial abscess and granuloma

Interventions

Intervention1: Comparing two drugs in prevention of seizures.: Compare Levetiracetam and Valproic acid in prevention of recurrence of seizures in neurocysticercosis Control Intervention1: Levetiraceta

Sponsors

Dr Abhinav Aggarwal
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All children diagnosed with Neurocysticercosis aged 5 to 18 years presenting with focal Seizure/GTCS episode

Exclusion criteria

Exclusion criteria: Previous treatment with anti epileptic drugs prior to visiting the hospital Seizures due to meningitis, major congenital anomaly, metabolic causes and febrile seizure.

Design outcomes

Primary

MeasureTime frame
Proportion of children with seizure recurrence at 3 month after starting treatment with study drugTimepoint: 3months—

Secondary

MeasureTime frame
Proportion of children who are seizure free for 6 monthsTimepoint: 6months—

Countries

India

Contacts

Public ContactDr Abhinav Aggarwal

Eras Lucknow Medical college and Hospital

drchhavi.nanda@gmail.com7408737635

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026